Search Results
Dec 07, 2025, 18:02 ET Matthews International Provides Update on Actions to Create Shareholder Value and Addresses Director Nominations
the Company, Alvaro Garcia-Tunon, Joseph C. Bartolacci, Katherine E. Dietze, Terry L. Dunlap, Lillian D. Etzkorn, Morgan K. O'Brien, Thomas Gebhardt, J. Michael Nauman, Aleta W. Richards, David A. Schawk, Francis S. Wlodarczyk and Brian D. Walters. Certain information about the compensation of the Company's
More news about: Matthews International Corporation
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published
More news about: Eli Lilly and Company
Dec 07, 2025, 12:00 ET BTDR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bitdeer Technologies Group Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
of Bitdeer's SEALMINER A4 project; (2) Defendants failed to disclose that the SEAL04 chip, projected to achieve a chip-level energy efficiency of 5 J/TH, would not be ready for use in the A4 rigs as represented; and (3) Mass production of the SEAL04 chip was not expected to begin in the second quarter
More news about: Bronstein, Gewirtz & Grossman, LLC
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
other therapies targeting key oncogenic drivers, early intervention can lead to better outcomes — and we see the same with zenocutuzumab," said Pritesh J. Gandhi, Chief Development Officer at Partner Therapeutics. "These findings strengthen our conviction that early targeted inhibition of the NRG1 pathway
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 12:28 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
https://doi.org/10.1111/epi.18689 Ren A, et al. J Medicinal Chem. 2025;68(11):10599-10618CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630
More news about: H. Lundbeck A/S
Dec 06, 2025, 12:25 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
https://doi.org/10.1111/epi.18689 Ren A, et al. J Medicinal Chem. 2025;68(11):10599-10618CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630
More news about: H. Lundbeck A/S
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
a single infusion of CARVYKTI for standard-risk patients may provide additional benefit to patients as early as second line of therapy," said Luciano J. Costa, M.D., Ph.D.,* Professor of Medicine at the University of Alabama and principal investigator of the CARTITUDE-4 study. "Treating patients with
More news about: Johnson & Johnson
Dec 05, 2025, 23:17 ET Investor Notice: Robbins LLP Informs Investors of the Bitdeer Technologies Group Securities Class Action
the fourth-generation SEALMINER A4 machine using its SEAL04 ASIC chip technology expected to have a chip energy efficiency of as low as 5J/TH that would help to increase revenue through self-mining and external sales in fiscal year 2025. Defendants continually reiterated that the SEAL04 research
More news about: Robbins LLP
Dec 05, 2025, 17:41 ET The Rosen Law Firm, P.A. Announces Updated Hearing Date for Proposed Class Action Settlement on Behalf of Investors in Vanguard Investor Target Retirement Funds
66 Hudson Boulevard New York, NY 10001Counsel for Vanguard DefendantsDaniel J. Kramer PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 1285 Avenue of the Americas New York, NY 10019Counsel
More news about: The Rosen Law Firm, P.A.
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Oncol. 2023;13:1170124.4 Lieblich A, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock RF. The management of non–muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol. 2018;11(2):144-148.5 Babjuk M, Burger M, Capoun O, et al.
More news about: Johnson & Johnson
Dec 05, 2025, 15:10 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bitdeer Technologies
Bitdeer's SEALMINER A4 project. Specifically, Defendants failed to disclose that the SEAL04 chip projected to have a chip-level energy efficiency of 5 J/TH would be ready for use in the A4 rigs with an expected mass production to begin in the second quarter 2025.On November 10, 2025, Bitdeer issued
More news about: Faruqi & Faruqi, LLP
Dec 05, 2025, 12:00 ET The Epstein Law Firm, P.A. Announces New Article by Managing Partner Michael J. Epstein: The Legal Gray Zones of a Three-Nation World Cup: Who Is Liable When Something Goes Wrong?
managing partner and trial attorney Michael J. Epstein, titled "
More news about: The Epstein Law Firm, P.A.
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Intermediate Analysis of the EpiCom TrialJ StevensPoster Number: 3.351
More news about: Jazz Pharmaceuticals plc
Dec 05, 2025, 09:00 ET Cirque du Soleil 'Auana Celebrates One Year in Hawai'i with Special Events and Anniversary Milestone
foundation of deep cultural collaboration, and seeing it resonate with locals and visitors over the past year has been incredibly meaningful," said Dr. Aaron J. Sala, Cultural Creative Producer. "Every performance is an opportunity for us to honor Hawai'i's stories with sincerity, respect and artistry, and we're
More news about: Cirque du Soleil 'Auana
Dec 05, 2025, 08:57 ET Morphy's Dec. 10-11 Fine & Decorative Arts Auction Ushers in the Holidays with Exquisite Jewels, Luxury Goods, Antiques and Art
pear-shape faceted natural diamonds ranging in size from 2.01cts to 0.37cts and having an approximate total weight of 14.60cts. The gems are graded H/I/J color with VVS1-SI1 clarity. Additionally, the 26 round, brilliant-cut natural diamonds range in size from 0.93cts to 0.13cts with an approximate total
More news about: Morphy Auctions
Dec 05, 2025, 08:46 ET New Study Confirms Safety and Major Cost Savings of Same-Day 360° Lumbar Fusion in Outpatient Surgery Centers
Steven J. Girdler, MD, of DISC Surgery Center, shows that even the most complex spinal fusions—anterior-posterior lumbar interbody fusions (ALIF + PSF, also
More news about: DISC Surgery Center
Dec 05, 2025, 08:00 ET Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
biopharmaceutical company developing novel small molecule modulators for oncology and autoimmune diseases, today announced the appointment of Daniel J. O'Connor as President & Chief Executive Officer, effective December 1, 2025.
More news about: Jubilant Therapeutics Inc.
Dec 05, 2025, 08:00 ET Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
ADMIRAL and COMMODORE trialsJ. WangType: Oral
More news about: Astellas Pharma Inc.
Dec 05, 2025, 08:00 ET Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
LinkedIn.Footnotes1 Gotlib J, Kluin-Nelemans, HC, George TI, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374:2530–2541.2 Sperr WR, Kundi M, Alvarez-Twose I, et al.
More news about: Blueprint Medicines, a Sanofi company
Dec 04, 2025, 17:23 ET Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations or Frank J. Johnson, Esq.(619) 814-4471
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 17:22 ET Ardent Health, Inc. (NYSE: ARDT) Investigation Alert: Johnson Fistel Reviews Accounting Adjustment and Liability Reserve Increase Following Stock Drop
performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego,
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 17:20 ET Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Sealed Air Buyout
this promotional communication, and Frank J. Johnson is the attorney responsible for its content.ContactJohnson Fistel, PLLP501 W. Broadway, Suite 800San Diego, CA 92101James Baker, Investor Relations – or – Frank J. Johnson, Esq.(619) 814-4471 |
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 17:16 ET Johnson Fistel Investigates Semrush (SEMR) Shareholders' Rights Following Adobe's $12 Buyout Offer
this promotional communication, and Frank J. Johnson is the attorney responsible for its content.ContactJohnson Fistel, PLLP501 W. Broadway, Suite 800San Diego, CA 92101James Baker, Investor Relations – or – Frank J. Johnson, Esq.(619) 814-4471 |
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 17:12 ET StubHub Holdings, Inc. (NYSE: STUB): Johnson Fistel Investigates Post-IPO Earnings Results Following Significant Stock Drop
performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.Contact:Johnson Fistel, PLLP 501 W. Broadway, Suite 800, San Diego,
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 17:10 ET Firefly Aerospace Inc. (NASDAQ: FLY) Securities Class Action: Johnson Fistel Reminds Investors of January 12 Deadline to Seek Lead Plaintiff Appointment
of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
More news about: Johnson Fistel, PLLP